Please assess the completion status of the following clinical trial:

Trial Title: Continuous Erector Spinae Block Versus Continuous Paravertebral Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA I - III status, undergoing unilateral thoracotomy for either esophageal atresia related intrathoracic procedures or other non-cardiac general surgical intrathoracic procedures.~Exclusion Criteria:~* Patients undergoing procedures including pleurodesis, pleural stripping, and decortication or other procedures with widely distributed pleural disruption.~* Patients with severe neurodevelopmental delays.~* Patients with previous chronic pain syndromes.~* Patients with a history of opioid treatment at any point in the 2 months prior to surgery.~* Lack of parental consent and/or child assent.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- continuous erector spinae block (Type: EXPERIMENTAL): An erector spinae block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.
- continuous paravertebral block (Type: ACTIVE_COMPARATOR): A paravertebral block is placed at end of the thoracotomy procedure, bolused with 1ml/kg 0.2% ropivacaine, then started on a 0.2ml/kg/hour continuous infusion of 0.2% ropivacaine. patients will have access to rescue opiates as needed by means of the standard PCA/NCA demand protocols utilized at BCH. Rescue analgesic consumption will be tabulated at 24, 48 and 72 hours, rendered as total opiate equivalents.

Based on this trial design, predict the completion outcome and termination type (if applicable).